2021 CMSC Annual Meeting

Abstracts

Platform-Disease Modifying Therapies

Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study

Background: The Work Productivity and Activity Impairment (WPAI) questionnaire is a patient-reported outcome that assesses percentage of...

Read More

Platform-Rehabilitation

Effects of weekly participation in a wellness program on people living with multiple sclerosis: a three-year analysis

Background: The Multiple Sclerosis Achievement Center (MSAC) conducts day wellness programs to address physical, cognitive and social...

Read More

Platform-Psychosocial

Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls

Background: Health-related quality of life (HRQOL) is reduced in persons with multiple sclerosis (MS) compared with the general population,...

Read More

Platform-Disease Modifying Therapies

Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review

Background: It is widely accepted that relapses of multiple sclerosis (MS) decrease during pregnancy; however, studies show an increased...

Read More

Platform-Disease Modifying Therapies

Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis

Background: Infection with Epstein-Barr virus (EBV) is a necessary risk factor for the development of multiple sclerosis (MS) Abrahamyan S...

Read More

Platform-Disease Management

How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey

Background: The COVID-19 crisis has created unanticipated changes in health care delivery for people living with multiple sclerosis (MS)....

Read More

Platform-Psychosocial

No One Really Plans to Have MS: Transition Readiness and Quality of Life in Pediatric Multiple Sclerosis

Background: Pediatric MS, defined as onset before the age of 18, is estimated to occur in over 8,000 children in the United States with...

Read More

Platform-Disease Management

Associations of Structural Visual Metrics with Moderate to Vigorous Physical Activity in Youth with Pediatric Onset Neuroinflammatory Disorders

Background: Previous research has shown that higher levels of moderate to vigorous physical activity (MVPA) associate with lower brain...

Read More

Platform-Rehabilitation

The Effect of Telerehabilitation on the Quality of Life and Fatigue of Patients with Multiple Sclerosis

Background: , Multiple Sclerosis is a chronic neurological disease, characterized by demyelination of neurons in the Central Nervous System...

Read More

Platform-Disease Management

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Background: The validated physician-completed MSProDiscussTM tool facilitates physician-patient interaction in evaluating early signs of...

Read More